Clinical Trials · NCT07437560
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Hudson Biotech
- Enrollment
- 60
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- Change from baseline in Vitiligo Area Scoring Index (VASI) total score